Biogeneric Pharma chooses MRC Systems for biopharma cleanrooms

MRC has been awarded the contract for the detailed design and build of 3,500 sqm of production area

The UAE-based cleanroom provider, MRC has been awarded the contract for the detailed design and build of Biogeneric Pharma's new production facility in Egypt. An exciting and challenging project that aims to change the landscape of biopharmaceutical production in the region.

Biogeneric Pharma (BGP) is involved in the development, production, and distribution of biopharmaceutical products. BGP boasts technologically advanced facilities and industry-leading partnerships, both cementing their position in their relevant field. The high-quality products are produced in line with global regulatory and safety standards.

Scope of the project

The project is based in Egypt and MRC's scope includes the design, supply and installation of MRC's cleanroom system and associated accessories.

It includes a phase 1 production area of approximately 2,000 sqm along with a phase 2 production area of another 1,500 sqm.

In addition to production; multiple warehousing and laboratory areas are being constructed on-site. MRC is providing their GRP cleanroom panelling system for this project, along with MRC GRP doors and a range of complementary accessories and products.

Current status

The project is on a fast track. It is being executed in two phases based on different production lines. Phase 1 of the production area is under installation. Site work is progressing well and MRC is currently supporting the integration of other services on-site including the HVAC works.

Phase 2 of the project is currently under production at MRC's flagship manufacturing facility in Dubai, UAE. MRC is working on a part design approval approach to ensure production and deliveries can be ongoing while final design details are still being discussed and closed. The flexibility of the GRP system on-site allows for this and is saving valuable time.

Across the globe, MRC is currently involved with a huge variety of pharmaceutical and wider life-science projects.

Companies